(II) 和铜 (II) 复合物的抗增殖活性,含有新型比奎诺素配体
Hager Sadek El-Beshti1, Zuhal Gercek2, Hakan Kayi3
1Atilim University, Department of Chemical Engineering, Incek, Ankara, Türkiye.
Metallomics : integrated biometal science
|January 6, 2024
概括
新的铜和化合物通过与DNA相互作用并诱导亡,显示出强大的抗癌活性. 这些新型前药候选者对各种癌症细胞系,特别是质母细胞瘤和HeLa细胞具有显著的潜力.
科学领域:
- 药用化学 医学化学
- 生物医学科学 生物医学科学
- 纳米技术纳米技术
背景情况:
- 癌症仍然是全球主要的死亡原因,需要开发新的抗瘤药物.
- 合成和评估基于金属的前药物为癌症治疗提供了一个有希望的策略.
研究的目的:
- 合成新型铜 (II) 和 (II) 复合物,其中含有比奎诺素配体,作为潜在的抗癌前药物.
- 研究这些合成金属复合物的DNA结合相互作用和细胞毒性作用.
主要方法:
- 合成四胺-2-) -6,6'-双素和四胺-2-) -6,6'-双素的金属复合物.
- 使用UV-Vis定位,热分解,粘度和度的DNA结合研究.
- 通过细胞活力,氧化应激,亡试验和DNA损伤试验对各种人类癌症细胞系进行抗瘤活性评估.
主要成果:
- 合成的复合物与小牛胸腺DNA (CT-DNA) 呈现自发相互作用,主要是通过范德瓦尔斯力和键.
- 铜 (II) 和 (II) 复合物对U87 (质母细胞瘤) 和HeLa (宫) 癌细胞系表现出显著的细胞毒性作用.
- Cl2,PtCl2和PtCl2显示出最高的DNA降解潜力和抗癌功效,通过活性氧物种生成诱导了亡.
结论:
- 新型的铜和双素复合体显示出有前途的抗癌活性和DNA结合能力.
- 这些金属复合物,特别是Cu (t) Cl2,Pt (t) Cl2和Pt (t) Cl2,是未来癌症治疗的潜在候选者.
- 对其作用机制和体内疗效的进一步研究是有必要的.
相关概念视频
Complexometric Titration: Ligands
954
Different monodentate and polydentate ligands are used as complexing agents in complexometric titration reactions. The formation of complexes by mono- and bidentate ligands involves two or more intermediate steps, limiting their use as complexing agents. In comparison, polydentate ligands can form complexes with metal ions in a single-step process, facilitating sharper end points. This means polydentate ligands, such as amino carboxylic acid derivatives, are most commonly employed in...
954
Extraction: Advanced Methods
447
Metal ions can be separated from one another by complexation with organic ligands–the chelating agent– to form uncharged chelates. Here, the chelating agent must contain hydrophobic groups and behave as a weak acid, losing a proton to bind with the metal. Since most organic ligands used in this process are insoluble or undergo oxidation in the aqueous phase, the chelating agent is initially added to the organic phase and extracted into the aqueous phase. The metal-ligand complex is...
447


